Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients

M. Polatli, A. Cakir, H. Ozcan, C. Yenisey, O. Cildag, Y. Yenicerioglu (Aydin, Turkey)

Source: Annual Congress 2004 - COPD: insights from structure and function
Session: COPD: insights from structure and function
Session type: Thematic Poster Session
Number: 839
Disease area: Airway diseases, Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Polatli, A. Cakir, H. Ozcan, C. Yenisey, O. Cildag, Y. Yenicerioglu (Aydin, Turkey). Microalbuminuria and von Willebrand factor antigen (vWF) as markers of endothelial dysfunction in COPD patients. Eur Respir J 2004; 24: Suppl. 48, 839

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Endothelial injury in COPD assessed by microalbuminuria (MAB) and von Willebrand factor levels (vWf:Ag) and activity (vWf:Ac)
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020


Changes of plasma von Willebrand factor in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 138s
Year: 2007

Expression of CD 34 and von Willebrand factor in pulmonary endothelium
Source: Eur Respir J 2001; 18: Suppl. 33, 243s
Year: 2001

Endotrophin and von Willebrand factor processing as predictive markers for mortality in the ECLIPSE COPD cohort
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019

Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 545s
Year: 2006

Elevated Von Willebrand Factor expression in the activated pulmonary endothelium of chronic thromboembolic pulmonary hypertension patients enhances platelet adhesion.
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020

Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnoeic episodes},
Source: Eur Respir J 2012; 40: 657-664
Year: 2012



Diagnostic value of Von Willebrand factor (VWF) in patients suffering from respiratory distress
Source: Annual Congress 2011 - Mechanisms of acute lung injury and mesenchymal cell treatment
Year: 2011



Endothelin, endothelial cells and von Willenbrandt factor in peripheral blood in asthma patients
Source: Eur Respir J 2003; 22: Suppl. 45, 77s
Year: 2003

PP308 – Endothelial injury in Chronic Obstructive Pulmonary Disease assessed by microalbuminuria (MAB) and von Willebrand factor levels and activity
Source: ERS Lung Science Conference 2021
Year: 2021

Unusually large von Willebrand factor multimers might be involved in cardiovascular events in patients with obstructive sleep apnea syndrome
Source: Eur Respir J 2006; 28: Suppl. 50, 415s
Year: 2006

Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 25s
Year: 2002

Circulating vascular endothelial growth factor and osteoporosis in patients with COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010

Serum vascular endothelial growth factor; an activation marker and prognostic indicator in sarcoidosis?
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005

Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019


Elevated factor FVIII:C levels in patients with pulmonary hypertension: a marked of endothelial dysfunction?
Source: Eur Respir J 2003; 22: Suppl. 45, 584s
Year: 2003

Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 350s
Year: 2005

Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 353s
Year: 2006

Hypercoagulability in patients with stable COPD assessed by coagulation factor levels
Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Year: 2020


PP220 – Hypercoagulability in patients with stable COPD assessed by coagulation factor levels
Source: ERS Lung Science Conference 2021
Year: 2021